Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study)

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|202-209

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 202-209

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response

By Rifkin Robert  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 714-722

Springer Publishing Company

Access to resources Recommend Favorite

Bortezomib in multiple myeloma

By Terpos Evangelos   Roussou Maria   Dimopoulos Meletios-Athanassios  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 5, 2008-05 ,pp. : 639-654

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib for multiple myeloma

By Popat Rakesh   Joel Simon   Oakervee Heather   Cavenagh Jamie  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 238-244

John Wiley & Sons Inc

Access to resources Recommend Favorite

An expanding VISTA for bortezomib in multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1645, 2008-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite